KLK4 Antibody
| Code | Size | Price |
|---|
| PSI-7445-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7445-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
KLK4 Antibody : ARM1, EMSP, PSTS, AI2A1, EMSP1, KLK-L1, PRSS17, kallikrein, Kallikrein-4, Enamel matrix serine proteinase 1
Application Note:
KLK4 antibody can be used for detection of KLK4 by Western blot at 1 - 2 μg/ml.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
Kallikreins (KLKs) belong to the serine protease family of proteolytic enzymes having diverse physiological functions (1). Kallikrein 4 (KLK4), also known as prostase or EMSP1 (enamel matrix serine protease 1), contains one peptidase S1 domain and the expression in prostate is regulated by hormone (1,2). Many kallikreins are implicated in carcinogenesis and have potential as novel cancer and other disease biomarkers (3). KLK4 may have additional roles such as functioning as one of the two major enamel proteases identified that process enamel matrix proteins. Defects in KLK4 are the cause of amelogenesis imperfecta hypomaturation type 2A1 (AI2A1) (4).
Background References:
- Stephenson SA, Verity K, Ashworth LK, et al. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J. Biol. Chem. 1999; 274:23210-4.
- Myers SA and Clements JA. Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE. J. Clin. Endocrinol. Metab. 2001; 86:2323-6.
- Kontos CK, Chantzis D, Papadopoulos IN, et al. Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. Cancer Lett. 2013; 330:106-12
- Shimizu-Okabe C, Yousef GM, Diamandis EP, et al. Expression of the kallikrein gene family in normal and Alzheimer's disease. Neuroreport 2001; 12:27447-51.
Buffer:
KLK4 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
KLK4 antibody was raised against a 15 amino acid peptide near the center of human KLK4.
The immunogen is located within amino acids 80 - 130 of KLK4 .
The immunogen is located within amino acids 80 - 130 of KLK4 .
NCBI Gene ID #:
9622
NCBI Official Name:
kallikrein-related peptidase 4
NCBI Official Symbol:
KLK4
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 28 kDa
Observed: 31kDa
Observed: 31kDa
Protein Accession #:
NP_004908
Protein GI Number:
89142741
Purification:
KLK4 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
KLK4 antibody is human specific. At least three isoforms of KLK4 are known to exist.
Swissprot #:
Q9Y5K2
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | KLK4 Peptide | PSI-7445P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|